Heart Failure Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook (2026-2035)

Heart Failure Market Overview

Heart failure is a complex cardiovascular condition marked by reduced cardiac output and fluid retention, leading to significant morbidity worldwide. The rising rates of hypertension, diabetes, and ischemic heart disease are poised to influence market demand. The market is anticipated to grow at a CAGR of 7.80% during the forecast period of 2026-2035, driven by the increasing prevalence of cardiometabolic disorders and rising healthcare awareness. Innovations in pharmacotherapies, minimally invasive devices, and digital monitoring tools are likely to impact patient management. Growing clinical awareness and evolving guideline recommendations could further affect adoption trends and market dynamics.

Heart Failure Market Growth Driver

Rising Cardiovascular Prevalence and High Rehospitalization Rates Fueling the Market Demand

The increasing global prevalence of cardiovascular diseases and persistently high rehospitalization rates are major drivers accelerating the market. According to the World Heart Federation, approximately 26 million people are diagnosed with heart failure worldwide, with an additional 11.7 million undiagnosed cases, bringing the total burden to nearly 37.7 million individuals. Furthermore, 1 in 5 people has a lifetime risk of developing heart failure. Nearly 50% of patients are readmitted within six months, and the five-year mortality rate ranges from 45-60%. These factors are increasing demand for innovative therapeutics and long-term disease management solutions, thereby supporting sustained market expansion.

Heart Failure Market Trends

The market is experiencing notable trends, including regulatory expansion in HFpEF therapies, growing global collaboration, and increasing device-based innovation.

Regulatory Expansion and Targeted HFpEF Developments Reshaping the Market Landscape

The increasing regulatory support for novel cardiovascular therapies and rising unmet needs in HFpEF populations are accelerating innovation in the market. For instance, in August 2024, Bayer reported positive results from the Phase III FINEARTS-HF trial evaluating finerenone in patients with heart failure and left ventricular ejection fraction ≥40%. The study demonstrated a significant reduction in cardiovascular death and heart failure events, supporting the potential expansion of targeted pharmacotherapies beyond traditional HFrEF treatment frameworks. Such late-stage clinical advancements highlight the growing therapeutic pipeline in HFpEF and are expected to enhance treatment options, drive competitive differentiation, and support long-term market expansion.

Global Healthcare System Optimization and Collaborative Innovation Expected to Propel the Heart Failure Market Expansion

Increasing international clinical collaboration and growing demand for standardized, guideline-directed care models are emerging as a defining trend in the heart failure market. In April 2025, a global roundtable organized by the Heart Failure Society of America and published in the International Journal of Heart Failure brought together experts from the United Kingdom, Italy, Japan, and India to address gaps in heart failure management. The initiative emphasized multidisciplinary care integration, improved registry infrastructure, and early therapeutic optimization, signaling a strategic shift toward coordinated, data-driven heart failure management across major healthcare systems.

Advancements and Ongoing Global Trial Enrollment to Boost the Heart Failure Market Innovation

Rising unmet therapeutic needs in HFpEF populations and growing investment in device-based cardiovascular innovation are accelerating evolution within the heart failure market. In September 2025, Medtronic initiated the global pivotal ELEVATE-HFpEF study evaluating personalized elevated cardiac pacing in this underserved patient segment. The randomized trial began enrollment in July 2025 and remains actively recruiting as of February 2026, targeting up to 700 participants worldwide. This ongoing investigation signals a potential expansion of device-indicated heart failure management beyond traditional pharmacotherapy-driven treatment pathways.

Japanese Regulatory Advancement and HFpEF Therapeutic Diversification Accelerating Heart Failure Market Penetration

The rising demand for evidence-based HFpEF therapies and expanding regulatory approvals across developed Asian economies are strengthening competitive dynamics in the heart failure market. In January 2026, Japan’s Ministry of Health, Labor and Welfare approved finerenone for adults with chronic heart failure and left ventricular ejection fraction (LVEF) ≥40%, broadening treatment options beyond its earlier renal indications. Supported by positive Phase III clinical outcomes, this approval reflects Japan’s proactive adoption of next-generation cardiovascular pharmacotherapies and signals increasing commercialization opportunities within the Asia-Pacific heart failure treatment landscape.

Heart Failure Market Share

Hospitals Expected to Lead the Market Share by End User

Hospitals are expected to lead the market, accounting for approximately 45% of the total market share. Their dominance is driven by the high volume of acute and chronic heart failure cases managed in inpatient settings, availability of advanced diagnostic and monitoring technologies, and capacity to implement guideline-directed therapies such as quadruple therapy for HFrEF and specialized HFpEF care. In addition, hospitals benefit from integrated cardiac care programs, well-established reimbursement frameworks, and growing adoption of remote monitoring and telehealth services, reinforcing their pivotal role in the heart failure treatment landscape.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Heart Failure Market Analysis by Region

The United States is expected to maintain market leadership, driven by one of the largest heart failure patient populations globally and a well-established healthcare infrastructure. For instance, in June 2025, the American College of Cardiology reported that approximately 6.7 million Americans were living with heart failure, with over 50% of cases attributed to HFpEF, and a 20-29% one-year mortality rate. The dominance is further supported by the rising prevalence of chronic cardiovascular conditions, increasing adoption of guideline-directed therapies, and expanding hospital-based treatment capacities.

Leading Players in the Heart Failure Market

Other key players in the market include Eli Lilly and Company, GSK plc, Abbott, Otsuka Pharmaceutical Co., Ltd., BIOTRONIK SE & Co. KG, and Boston Scientific Corporation.

Heart Failure Market Segmentation

Key Questions Answered in the Heart Failure Market Report

• What was the heart failure market value in 2025?
• What is the heart failure market forecast outlook for 2026-2035?
• What are the major factors aiding the heart failure market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major heart failure market trends?
• Which types are expected to dominate the market segment?
• Which treatment type is projected to lead the market segment?
• Which end user is likely to dominate the market segment?
• Who are the key players involved in the heart failure market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?